A first-line regimen combining sintilimab, IBI305 (a biosimilar version of bevacizumab), and chemotherapy showed promise in advanced gastric and gastroesophageal junction adenocarcinoma, according to a clinical study reported by Cheng, Zhang, Hu and colleagues. The trial tested an immunotherapy-plus-targeted-antiangiogenic approach alongside standard chemotherapy. The three-part strategy reflects continued efforts to build durable responses by pairing PD-1 pathway inhibition with VEGF-axis blockade and cytotoxic treatment. For a setting where survival gains have been incremental, regimen simplification and predictable safety profiles remain central. Key next steps for biotech stakeholders are the magnitude of response, durability, and any subgroup performance signals that could support later-stage development or comparative studies. The study also strengthens momentum for biosimilar integration in multi-drug oncology regimens, where cost and access can influence adoption.